Sprim Ventures

Founder and Managing Partner Michael Guez leads the firm from Singapore alongside Managing Partner Jon Soberg, who runs US operations out of San Francisco. Guez is a second-generation member of the family behind SPRIM, the global health consultancy. Investment decisions draw on the firm's partnership team and its C-LEVEL roster of sector operators.

Sprim sources through its global healthcare consultancy SPRIM, which maintains relationships with pharmaceutical, nutrition, and consumer-health clients across 19 offices. The consultancy gives the venture arm early visibility into regulatory shifts, reimbursement changes, and clinician adoption patterns before they surface in public markets. The firm's presence in Singapore also surfaces Southeast Asian health-tech startups that sit outside typical Sand Hill Road deal flow.

Yes. Through its C-LEVEL consultancy, Sprim places full-time operators inside portfolio companies on six-to-eighteen-month engagements. These executives handle regulatory strategy, product-market fit, and go-to-market execution — areas where early-stage health-tech founders often lack in-house expertise. This model reduces the operational risk that kills many pre-revenue health companies.

Sprim concentrates exclusively on human and animal health, nutrition, and wellness. It does not invest in generalist software, fintech, enterprise SaaS, or pure biotech plays outside its consumer-facing thesis areas. The firm has publicly stated its intention to lean further into women's health and longevity, signaling a narrower — not broader — sector aperture going forward.

Founding capital originated with the Guez family, who built SPRIM into a global health consultancy serving multinational pharmaceutical and consumer companies. The firm now raises from a mix of family offices, institutional allocators, and high-net-worth individuals, with family capital remaining a core anchor. The exact AUM composition is not publicly disclosed.